News

Incyte to acquire Villaris Therapeutics and with it auremolimab a proposed treatment for Vitiligo

Read time: 1 mins

Published:5th Oct 2022

Incyte has announced that the Company has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development of novel antibody therapeutics for vitiligo. Its lead asset, auremolimab (VM6), an anti-IL-15R monoclonal antibody (mAb), is expected to enter clinical development in 2023

Type: industry

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Industry news

TreeFrog Therapeutics licenses C-Stem technology to Vertex Pharma

Vertex Pharmaceuticals Incorporated and TreeFrog Therapeutics announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-Stem, to optimize production of Vertex's cell therapies for type 1 diabetes (T1D)

1 mins

Industry news

Bruker to acquire assets of Nanostring

Bruker will pay about $392.6 million in cash to acquire most of the assets of Nanostring, a provider of research tools for spatial biology and gene expression according to Nanostring

1 min

Industry news

Eyenovia Inc.,to accelerate development of MicroPine and explore alternatives to maximize shareholder value.

Eyenovia, Inc. announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia (MicroPine) and initiated a process to explore strategic alternatives to maximize shareholder value

1 min

See all news